Abstract
Thirty-nine caudatin analogs were designed and synthesized. Their anti-hepatitis B virus (HBV) activities were evaluated in vitro. Among them, twenty-three compounds showed much better anti-HBV activity than caudatin, and eleven compounds significantly inhibited the HBV DNA replication with IC50 values < 10 μM. Interestingly, three compounds (22, 28, 29) exhibited excellent activity against the secretion of HBsAg (IC50 = 63.02 μM, 52.81 μM, 56.08 μM), HBeAg (IC50 = 204.80 μM, 173.51 μM, 70.39 μM), along with HBV DNA replication (IC50 = 24.55 μM, 5.69 μM, 8.23 μM) with lower cytotoxicity. The structure-activity relationships (SARs) of these caudatin analogs were also discussed.
Keywords: Anti-HBV activity, Caudatin analogs, Hepatitis B e Antigen (HBeAg), Hepatitis B Surface Antigen (HBsAg), HBV DNA replication, Structure-activity relationships(SARs), Synthesis.
Graphical Abstract
Medicinal Chemistry
Title:Design, Synthesis and Biological Evaluation of Caudatin Analogs as Potent Hepatitis B Virus Inhibitors
Volume: 11 Issue: 2
Author(s): Li-Jun Wang, Hao Chen, Yun-Bao Ma, Xiao-Yan Huang, Chang-An Geng, Xue-Mei Zhang and Ji-Jun Chen
Affiliation:
Keywords: Anti-HBV activity, Caudatin analogs, Hepatitis B e Antigen (HBeAg), Hepatitis B Surface Antigen (HBsAg), HBV DNA replication, Structure-activity relationships(SARs), Synthesis.
Abstract: Thirty-nine caudatin analogs were designed and synthesized. Their anti-hepatitis B virus (HBV) activities were evaluated in vitro. Among them, twenty-three compounds showed much better anti-HBV activity than caudatin, and eleven compounds significantly inhibited the HBV DNA replication with IC50 values < 10 μM. Interestingly, three compounds (22, 28, 29) exhibited excellent activity against the secretion of HBsAg (IC50 = 63.02 μM, 52.81 μM, 56.08 μM), HBeAg (IC50 = 204.80 μM, 173.51 μM, 70.39 μM), along with HBV DNA replication (IC50 = 24.55 μM, 5.69 μM, 8.23 μM) with lower cytotoxicity. The structure-activity relationships (SARs) of these caudatin analogs were also discussed.
Export Options
About this article
Cite this article as:
Wang Li-Jun, Chen Hao, Ma Yun-Bao, Huang Xiao-Yan, Geng Chang-An, Zhang Xue-Mei and Chen Ji-Jun, Design, Synthesis and Biological Evaluation of Caudatin Analogs as Potent Hepatitis B Virus Inhibitors, Medicinal Chemistry 2015; 11 (2) . https://dx.doi.org/10.2174/1573406410666140902111326
DOI https://dx.doi.org/10.2174/1573406410666140902111326 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Software Analysis of Two-Dimensional Electrophoretic Gels in Proteomic Experiments
Current Bioinformatics Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery Endogenous Ligand Bias by Chemokines: Implications at the Front Lines of Infection and Leukocyte Trafficking
Endocrine, Metabolic & Immune Disorders - Drug Targets Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody
Current Molecular Pharmacology Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Combination of Salinomycin and AZD3463 Reveals Synergistic Effect on Reducing the Viability of T98G Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets Research in Rare Diseases - When Less is More
Current Medicinal Chemistry Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets COX-2 Docking Structural Analysis with Phytochemical Extracts of Rosemary: A Possible Cytotoxicity on Head and Neck Squamous Cell Carcinoma Cell Line (HEp-2)
Anti-Cancer Agents in Medicinal Chemistry